Bertilsson L - Search Results

1

Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.

Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J, Bertilsson L. Carrillo JA, et al. Among authors: bertilsson l. Ther Drug Monit. 2000 Aug;22(4):409-17. doi: 10.1097/00007691-200008000-00008. Ther Drug Monit. 2000. PMID: 10942180

2

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.

Llerena A, Dahl ML, Ekqvist B, Bertilsson L. Llerena A, et al. Among authors: bertilsson l. Ther Drug Monit. 1992 Jun;14(3):261-4. doi: 10.1097/00007691-199206000-00014. Ther Drug Monit. 1992. PMID: 1412613

3

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML, Bertilsson L. Christensen M, et al. Among authors: bertilsson l. Clin Pharmacol Ther. 2002 Mar;71(3):141-52. doi: 10.1067/mcp.2002.121788. Clin Pharmacol Ther. 2002. PMID: 11907488 Clinical Trial.

4

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.

Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, Lindström L, Rodriguez de la Rubia I, Ramos S, Benitez J. Bertilsson L, et al. Br J Clin Pharmacol. 1994 Nov;38(5):471-3. doi: 10.1111/j.1365-2125.1994.tb04385.x. Br J Clin Pharmacol. 1994. PMID: 7893591 Free PMC article. Clinical Trial.

5

Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations.

Reviriego J, Bertilsson L, Carrillo JA, Llerena A, Valdivielso MJ, Benítez J. Reviriego J, et al. Among authors: bertilsson l. Eur J Clin Pharmacol. 1993;44(6):593-5. doi: 10.1007/BF02440867. Eur J Clin Pharmacol. 1993. PMID: 8405020

6

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.

Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodríguez I, Bertilsson L. Carrillo JA, et al. Among authors: bertilsson l. Clin Pharmacol Ther. 1996 Aug;60(2):183-90. doi: 10.1016/S0009-9236(96)90134-4. Clin Pharmacol Ther. 1996. PMID: 8823236

7

Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study.

Härtter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, Röjdmark S, Bertilsson L. Härtter S, et al. Among authors: bertilsson l. Clin Pharmacol Ther. 2001 Jul;70(1):10-6. doi: 10.1067/mcp.2001.116512. Clin Pharmacol Ther. 2001. PMID: 11452239

8

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.

Llerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L. Llerena A, et al. Among authors: bertilsson l. Ther Drug Monit. 1992 Apr;14(2):92-7. doi: 10.1097/00007691-199204000-00003. Ther Drug Monit. 1992. PMID: 1585408

9

Enantioselective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline.

Dahl ML, Nordin C, Bertilsson L. Dahl ML, et al. Among authors: bertilsson l. Ther Drug Monit. 1991 May;13(3):189-94. doi: 10.1097/00007691-199105000-00001. Ther Drug Monit. 1991. PMID: 1926270

10

Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Ghotbi R, et al. Among authors: bertilsson l. Eur J Clin Pharmacol. 2007 Jun;63(6):537-46. doi: 10.1007/s00228-007-0288-2. Epub 2007 Mar 17. Eur J Clin Pharmacol. 2007. PMID: 17370067

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

340 results

Search Page

Filters